

Effective: 4/2004

Revised: 02/28/06, 11/7/11, 4/17/12, 7/23/13, 8/25/15 Reviewed/No Updates: 1/28/13, 2/13/14, 2/12/15, 2/11/16, 2/9/17, 2/8/18, 2/14/19, 2/13/20, 2/11/21, 2/17/22, 2/2/23,

2/8/24, 2/20/25

# THE MORNING AFTER PILL (TMAP)

# **Policy**

California is one of many States of the union that have authorized physicians to prescribe the morning pill (TMAP) to any woman requesting such medication within 72 hours of intercourse, without having to do an examination - (SB 1169). VCHCP provides the benefit to its members.

California has also put into place a protocol which allows any pharmacist who wishes to participate to dispense TMAP without a prescription from a physician. Participating pharmacists are required to take a short training course provided by the State. Pharmacists are also required to provide the member with a California Board of Pharmacy flyer describing the treatment.

All VCHCP PCP's and OB/Gyn specialists should be prepared to either prescribe or dispense or refer the member to a provider who will prescribe or dispense "TMAP" any time it is requested, without having to do a History and Physical examination.

California has also given patients the right to purchase the morning after pill OTC without a prescription from any retail store along with a requirement that health care plans reimburse enrollees for the cost of the drug if this OTC purchase option is exercised by an enrollee.

The Protocol for TMAP allows for 3 dosing schedules as follows:

- PREVEN Lo Ovral (Ethinyl Estradiol 0.5mg, Levonorgestrel 0.25 mg)
   Total Dose = 4 Tablets
   2 Tablets now and repeat in 12 hours.
- PLAN B Two-dose regimen (Levonorgestrel 0.75 mg)
   Total Dose = 2 Tablets
   1 Tablet now and repeat in 12 hours

One Step (Levonorgestrel 1.5 mg)
Total Dose = 1 Tablet
1 Tablet now

3. Any High Dose regular birth control pillTotal Dose = 4 Tablets2 Tablets now and repeat in 12 hours

Note: Preven has a 75% efficacy rate and Plan B has an 89% efficacy rate.



Effective: 4/2004

Revised: 02/28/06, 11/7/11, 4/17/12, 7/23/13, 8/25/15 Reviewed/No Updates: 1/28/13, 2/13/14, 2/12/15, 2/11/16, 2/9/17, 2/8/18, 2/14/19, 2/13/20, 2/11/21, 2/17/22, 2/2/23,

2/8/24, 2/20/25

Literature is replete with articles attesting to the safety of the above medication.

#### **Procedure**

PCPs and OB/Gyn specialists will prescribe TMAP or refer the member to a provider who will prescribe TMAP upon request of member, without requiring an examination.

Alternatively, the member may be directed by the provider, or the provider's staff to a pharmacy for direct dispensing without prescription.

If a female enrollee requests reimbursement for TMAP purchased OOP, current law allows VCHCP 63 days to issue payment. (see below for Reimbursement Claim Form)

### **Exceptions/Limitations**

Male enrollees

**NOTE**: Nothing in this policy is intended to diminish the Plan's right to investigate fraud, nor does this policy preclude the Plan from delaying or denying coverage for this drug if the Plan, in good faith, suspects fraud or "straw purchasing" on part of the enrollee.

#### A. Attachments: Reimbursement Claim Form

#### **B.** References

Barbieri, Robert L. & Zieman, Mimi. Emergency contraception. Version 13.3 August 2005. 12/29/05 www.uptodate.com

Select Drug Information from Lexi-Comp Online™ Copyright (1978 to present) Lexi-Comp, Inc.

©2013UpToDatewww.uptodate.com ® -

Epocrates 2013 - www.epocrates.com

#### C. History

Reviewed by: Sheldon Haas, MD and David Chernof, MD; Date: 04/04/04

QA Committee; Date: 04/20/04

Reviewed by: Cynthian Wilhelmy MD; Date: 01/17/06



Effective: 4/2004

Revised: 02/28/06, 11/7/11, 4/17/12, 7/23/13, 8/25/15 Reviewed/No Updates: 1/28/13, 2/13/14, 2/12/15, 2/11/16, 2/9/17, 2/8/18, 2/14/19, 2/13/20, 2/11/21, 2/17/22, 2/2/23,

2/8/24, 2/20/25

Committees: P&T 01/23/06; UM 02/06/06; QA 02/28/06

Reviewed by: Albert Reeves, MD; Date: 11/7/11
Committees: UM on 11/10/11; QA on 11/22/11
Reviewed by: Albert Reeves, MD; Date: 4/17/12
Committee Reviews: UM on 5/10/12 & QA on 5/22/12
Reviewed/No Updates: Albert Reeves, MD; Date: 1/28/13
Committee Review: UM on 2/14/13; QA on 2/26/13
Reviewed/ Updates: Albert Reeves, MD; Date: 07/23/13
Committee Review: UM on 08/8/13 & QA on 08/27/13
Reviewed/No Updates: Catherine Sanders, MD
Committee Review: UM on 2/13/14 & QA on 2/25/14
Reviewed/No Updates: Catherine Sanders, MD

Committee Review: UM on 02/12/2015 & QA on 02/24/2015 Reviewed/ Updates: Catherine Sanders, MD; Date: 08/25/15

Committee Review: UM on 11/12/15 & QA on 11/24/15

Reviewed/No Updates: Faustine Dela Cruz, RN & Catherine Sanders, MD Committee Review: UM: February 11, 2016; QAC: February 23, 2016 Reviewed/No Updates: Catherine Sanders, MD & Robert Sterling, MD Committee Review: UM: February 9, 2017; QAC: February 28, 2017 Reviewed/No Updates: Catherine Sanders, MD & Robert Sterling, MD Committee Review: UM: February 8, 2018; QAC: February 27, 2018 Reviewed/No Updates: Catherine Sanders, MD & Robert Sterling, MD Committee Review: UM: February 14, 2019; QAC: February 26, 2019 Reviewed/No Updates: Howard Taekman, MD & Robert Sterling, MD Committee Review: UM: February 13, 2020; QAC: February 25, 2020 Reviewed/No Updates: Howard Taekman, MD & Robert Sterling, MD Committee Review: UM: February 11, 2021; QAC: February 23, 2021 Reviewed/No Updates: Howard Taekman, MD & Robert Sterling, MD Committee Review: UM: February 17, 2022; QAC: February 22, 2022 Reviewed/No Updates: Howard Taekman, MD & Robert Sterling, MD Committee Review: UM: February 2, 2023; QAC: February 7, 2023 Reviewed/No Updates: Howard Taekman, MD & Robert Sterling, MD Committee Review: UM: February 8, 2024; QAC: February 27, 2024 Reviewed/Updated by: Howard Taekman, MD & Robert Sterling, MD

Committee Review: UM: February 20, 2025; QAC: February 25, 2025

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
2/9/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual Review



Effective: 4/2004

Revised: 02/28/06, 11/7/11, 4/17/12, 7/23/13, 8/25/15 Reviewed/No Updates: 1/28/13, 2/13/14, 2/12/15, 2/11/16, 2/9/17, 2/8/18, 2/14/19, 2/13/20, 2/11/21, 2/17/22, 2/2/23,

2/8/24, 2/20/25

2/8/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual Review
2/14/19	No	Catherine Sanders, MD; Robert Sterling, MD	Annual Review
2/13/20	No	Howard Taekman, MD; Robert Sterling, MD	Annual Review
2/11/21	No	Howard Taekman, MD; Robert Sterling, MD	Annual Review
2/17/22	No	Howard Taekman, MD; Robert Sterling, MD	Annual Review
2/2/23	No	Howard Taekman, MD; Robert Sterling, MD	Annual Review
2/8/24	No	Howard Taekman, MD; Robert Sterling, MD	Annual Review
2/20/25	Yes	Howard Taekman, MD; Robert Sterling, MD	Replaced "the Plan
			shall immediately,
			but not more than
			120 days after Plan's
			receipt of product
			receipt, reimburse
			the enrollee for the
			cost of the drug "
			with "requests
			reimbursement for
			TMAP purchased
			OOP, current law
			allows VCHCP 63
			days to issue
			payment "Added
			Reimbursement
			Claim form

